Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-blind placebo-controlled study of ivacaftor in cystic fibrosis with G551D mutation using hyperpolarized helium-3 MRI
2017-000672-28Phase 2
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in cystic fibrosis (CF) comparing Ivacaftor with Placebo (2 arms). Primary endpoint: Change in total ventilation defect by 3He-MRI (Part A).
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-000672-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000672-28.